HCV: the best cure possible or the best possible cure?
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies
Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial
A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1
Cognitive function and endogenous cytokine levels in children with chronic hepatitis C
Role of complement component C4 in treatment response and disease progression in chronic hepatitis C patients
Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir
‘HepConomics’: cost-effective, indeed, but how can we pay for it?